Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed metastatic or unresectable cancer largely confined to the peritoneal cavity
• * Fully resected and/or electrocauterized metastatic disease involving the peritoneum (stage IV, no residual disease) allowed
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin normal
• SGOT/SGPT no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine normal OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other:
• No history of allergy to platinum compounds or antiemetics that would preclude study
• No other uncontrolled illness (e.g., active infection)
• No evidence of neuropathy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• Surgery:
• See Disease Characteristics
• Other:
• No other concurrent investigational agents
• No concurrent antiretroviral therapy (HAART)